STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant

Trial Profile

STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2017

At a glance

  • Drugs Aromatase inhibitors (Primary) ; Fulvestrant (Primary) ; Sulforafan (Primary) ; Tamoxifen (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STEM
  • Sponsors Evgen Pharma
  • Most Recent Events

    • 22 Dec 2017 Last checked against ClinicalTrials.gov record.
    • 23 Nov 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
    • 23 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top